{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T01:10:15Z","timestamp":1782609015338,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,9,24]],"date-time":"2011-09-24T00:00:00Z","timestamp":1316822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00213-011-2499-6","type":"journal-article","created":{"date-parts":[[2011,9,23]],"date-time":"2011-09-23T07:57:34Z","timestamp":1316764654000},"page":"519-528","source":"Crossref","is-referenced-by-count":21,"title":["Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients"],"prefix":"10.1007","volume":"220","author":[{"given":"Lior","family":"Greenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Lorberboym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Alkelai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Zozulinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuri","family":"Lifshytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Djaldetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,24]]},"reference":[{"issue":"6","key":"2499_CR1","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajmg.b.30746","volume":"147B","author":"AF Al Hadithy","year":"2008","unstructured":"Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR, Matroos GE, van Os J, Hoek HW, van Harten PN (2008) Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B 147B(6):890\u2013897","journal-title":"Am J Med Genet B"},{"issue":"2","key":"2499_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hup.997","volume":"24","author":"AF Al Hadithy","year":"2009","unstructured":"Al Hadithy AF, Wilffert B, Bruggeman R, Stewart RE, Brouwers JR, Matroos GE, Hoek HW, van Harten PN (2009) Lack of association between antipsychotic-induced parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol 24(2):123\u2013128","journal-title":"Hum Psychopharmacol"},{"issue":"8","key":"2499_CR3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/humu.21042","volume":"30","author":"M Alaerts","year":"2009","unstructured":"Alaerts M, Del-Favero J (2009) Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future. Hum Mutat 30(8):1139\u20131152","journal-title":"Hum Mutat"},{"issue":"3","key":"2499_CR4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00213-009-1627-z","volume":"206","author":"A Alkelai","year":"2009","unstructured":"Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B (2009) Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 206(3):491\u2013499","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"2499_CR5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","volume":"12","author":"MJ Arranz","year":"2007","unstructured":"Arranz MJ, de Leon J (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12(8):707\u2013747","journal-title":"Mol Psychiatry"},{"key":"2499_CR6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.1961.03040120016004","volume":"175","author":"F Ayd","year":"1961","unstructured":"Ayd F (1961) A survey of drug-induced extrapyramidal reaction. JAMA 175:1054\u20131060","journal-title":"JAMA"},{"issue":"20","key":"2499_CR7","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/hmg\/11.20.2517","volume":"11","author":"VS Basile","year":"2002","unstructured":"Basile VS, Masellis M, Potkin SG, Kennedy JL (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11(20):2517\u20132530","journal-title":"Hum Mol Genet"},{"issue":"7303","key":"2499_CR8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature09103","volume":"466","author":"DM Behar","year":"2010","unstructured":"Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J, Rootsi S, Chaubey G, Kutuev I, Yudkovsky G, Khusnutdinova EK, Balanovsky O, Semino O, Pereira L, Comas D, Gurwitz D, Bonne-Tamir B, Parfitt T, Hammer MF, Skorecki K, Villems R (2010) The genome-wide structure of the Jewish people. Nature 466(7303):238\u2013242","journal-title":"Nature"},{"issue":"Suppl 3","key":"2499_CR9","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1016\/S1353-8020(08)70042-7","volume":"13","author":"J Booij","year":"2007","unstructured":"Booij J, Knol RJ (2007) SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord 13(Suppl 3):S425\u2013S428","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2499_CR10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.43.3_Part_1.552","volume":"43","author":"DJ Burn","year":"1993","unstructured":"Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 43(3):552\u2013556","journal-title":"Neurology"},{"issue":"1","key":"2499_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/jnp.12.1.34","volume":"12","author":"MP Caligiuri","year":"2000","unstructured":"Caligiuri MP, Peavy G (2000) An instrumental study of the relationship between extrapyramidal signs and psychosis in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 12(1):34\u201339","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"2499_CR12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcdb.2004.10.006","volume":"16","author":"AB Cantor","year":"2005","unstructured":"Cantor AB, Orkin SH (2005) Coregulation of GATA factors by the Friend of GATA (FOG) family of multitype zinc finger proteins. Semin Cell Dev Biol 16(1):117\u2013128","journal-title":"Semin Cell Dev Biol"},{"issue":"supp 9","key":"2499_CR13","first-page":"S25","volume":"65","author":"DE Casey","year":"2004","unstructured":"Casey DE (2004) Pathophysiology of antipsychotics drug-induced movement disorders. J Clin Psychiatry 65(supp 9):S25\u2013S28","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2499_CR14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/14622416.10.2.161","volume":"10","author":"JJ Crowley","year":"2009","unstructured":"Crowley JJ, Sullivan PF, McLeod HL (2009) Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 10(2):161\u2013163","journal-title":"Pharmacogenomics"},{"issue":"4","key":"2499_CR15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0031-6997(25)06933-9","volume":"47","author":"M Ebadi","year":"1995","unstructured":"Ebadi M, Srinivasan SK (1995) Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 47(4):575\u2013604","journal-title":"Pharmacol Rev"},{"issue":"7","key":"2499_CR16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1176\/ajp.115.7.577","volume":"115","author":"FA Freyhan","year":"1959","unstructured":"Freyhan FA (1959) Therapeutic implications of differential effects of new phenothiazine compounds. Am J Psychiatry 115(7):577\u2013585","journal-title":"Am J Psychiatry"},{"issue":"7","key":"2499_CR17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FPC.0b013e32800ffbb4","volume":"17","author":"L Greenbaum","year":"2007","unstructured":"Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, Katz E, Kotler M, Olender T, Deshpande SN, Lancet D, Ben-Asher E, Lerer B (2007) Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 17(7):519\u2013528","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"2499_CR18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/tpj.2008.6","volume":"9","author":"L Greenbaum","year":"2009","unstructured":"Greenbaum L, Smith RC, Rigbi A, Strous RD, Teltsh O, Kanyas K, Korner M, Lancet D, Ben-Asher E, Lerer B (2009) Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism the 3\u2032 untranslated region. Pharmacogenomics J 9(2):103\u2013110","journal-title":"Pharmacogenomics J"},{"issue":"16","key":"2499_CR19","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1002\/mds.23377","volume":"25","author":"L Greenbaum","year":"2010","unstructured":"Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B (2010) Evidence for association of the GLI2 gene with tardive dyskinesia in chronic schizophrenia patients. Mov Disord 25(16):2809\u20132817","journal-title":"Mov Disord"},{"issue":"5","key":"2499_CR20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00228-007-0450-x","volume":"64","author":"A Gunes","year":"2008","unstructured":"Gunes A, Dahl ML, Spina E, Scordo MG (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64(5):477\u2013482","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"2499_CR21","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/hup.918","volume":"23","author":"PM Haddad","year":"2008","unstructured":"Haddad PM, Dursun SM (2008) Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 23(Suppl 1):S15\u2013S26","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"2499_CR22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/schbul\/23.4.567","volume":"23","author":"TE Hansen","year":"1997","unstructured":"Hansen TE, Casey DE, Hoffman WF (1997) Neuroleptic intolerance. Schizophr Bull 23(4):567\u2013582","journal-title":"Schizophr Bull"},{"issue":"11","key":"2499_CR23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s007020100006","volume":"108","author":"S Hassin-Baer","year":"2001","unstructured":"Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108(11):1299\u20131308","journal-title":"J Neural Transm"},{"issue":"1","key":"2499_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neulet.2009.11.043","volume":"469","author":"M Higa","year":"2010","unstructured":"Higa M, Ohnuma T, Maeshima H, Hatano T, Hanzawa R, Shibata N, Sakai Y, Suzuki T, Arai H (2010) Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP). Neurosci Lett 469(1):55\u201359","journal-title":"Neurosci Lett"},{"issue":"Suppl 3","key":"2499_CR25","doi-asserted-by":"crossref","first-page":"iii22","DOI":"10.1007\/s00415-006-3004-8","volume":"253","author":"G Hirose","year":"2006","unstructured":"Hirose G (2006) Drug induced parkinsonism: a review. J Neurol 253(Suppl 3):iii22\u2013iii24","journal-title":"J Neurol"},{"issue":"8","key":"2499_CR26","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.bjc.6605276","volume":"101","author":"V Hoene","year":"2009","unstructured":"Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C (2009) GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. Br J Cancer 101(8):1481\u20131489","journal-title":"Br J Cancer"},{"issue":"3","key":"2499_CR27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2499_CR28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2377-5-5","volume":"5","author":"S Janno","year":"2005","unstructured":"Janno S, Holi MM, Tuisku K, Wahlbeck K (2005) Validity of Simpson\u2013Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol 5(1):5","journal-title":"BMC Neurol"},{"issue":"3","key":"2499_CR29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00213-010-2079-1","volume":"214","author":"M Kasten","year":"2011","unstructured":"Kasten M, Br\u00fcggemann N, K\u00f6nig IR, Doerry K, Steinlechner S, Wenzel L, Lohmann K, Klein C, Lencer R (2011) Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl) 214(3):729\u2013736","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"2499_CR30","first-page":"20","volume":"44","author":"V Lerner","year":"2007","unstructured":"Lerner V, Libov I, Kapstan A, Miodownik C, Dwolatzky T, Levine J (2007) The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci 44(1):20\u201328","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"12","key":"2499_CR31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209\u20131223","journal-title":"N Engl J Med"},{"issue":"4","key":"2499_CR32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.20748","volume":"21","author":"M Lorberboym","year":"2006","unstructured":"Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R (2006) [123I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 21(4):510\u2013514","journal-title":"Mov Disord"},{"issue":"6","key":"2499_CR33","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1128\/MCB.19.6.4495","volume":"19","author":"JR Lu","year":"1999","unstructured":"Lu JR, McKinsey TA, Xu H, Wang DZ, Richardson JA, Olson EN (1999) FOG-2, a heart- and brain-enriched cofactor for GATA transcription factors. Mol Cell Biol 19(6):4495\u20134502","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2499_CR34","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1212\/WNL.57.11.2089","volume":"57","author":"K Marek","year":"2001","unstructured":"Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57(11):2089\u20132094","journal-title":"Neurology"},{"key":"2499_CR35","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jama.1962.03050500059015d","volume":"182","author":"C Medinar","year":"1962","unstructured":"Medinar C, Kramer MD, Kurland AA (1962) Biperiden in the treatment of phenothiazine-induced extrapyramidal reactions. JAMA 182:1127\u20131128","journal-title":"JAMA"},{"issue":"1","key":"2499_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79\u2013104","journal-title":"Mol Psychiatry"},{"issue":"4","key":"2499_CR37","first-page":"584","volume":"41","author":"PD Mozley","year":"2000","unstructured":"Mozley PD, Schneider JS, Acton PD, Pl\u00f6ssl K, Stern MB, Siderowf A, Leopold NA, Li PY, Alavi A, Kung HF (2000) Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 41(4):584\u2013589","journal-title":"J Nucl Med"},{"issue":"7","key":"2499_CR38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archgenpsychiatry.2010.69","volume":"67","author":"MJ Owen","year":"2010","unstructured":"Owen MJ, Craddock N, O'Donovan MC (2010) Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiatry 67(7):667\u2013673","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2499_CR39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559\u2013575","journal-title":"Am J Hum Genet"},{"issue":"16","key":"2499_CR40","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/archinte.165.16.1882","volume":"165","author":"PA Rochon","year":"2005","unstructured":"Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand SL, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH (2005) Atypical antipsychotics and parkinsonism. Arch Intern Med 165(16):1882\u20131888","journal-title":"Arch Intern Med"},{"key":"2499_CR41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"G Simpson","year":"1970","unstructured":"Simpson G, Angus MP (1970) Scale for assessment extrapyramidal side effects. Acta Psychiatr Scand 212:11\u201319","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"2499_CR42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1461145705005110","volume":"8","author":"R Smith","year":"2005","unstructured":"Smith R, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 8(2):183\u2013194","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8411","key":"2499_CR43","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0140-6736(84)91516-2","volume":"2","author":"PJ Stephen","year":"1984","unstructured":"Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2(8411):1082\u20131083","journal-title":"Lancet"},{"issue":"10","key":"2499_CR44","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biopsych.2006.11.010","volume":"61","author":"PF Sullivan","year":"2007","unstructured":"Sullivan PF (2007) Spurious genetic associations. Biol Psychiatry 61(10):1121\u20131126","journal-title":"Biol Psychiatry"},{"issue":"6","key":"2499_CR45","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mp.2008.25","volume":"13","author":"PF Sullivan","year":"2008","unstructured":"Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13(6):570\u2013584","journal-title":"Mol Psychiatry"},{"issue":"3","key":"2499_CR46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1073\/pnas.96.3.956","volume":"96","author":"EC Svensson","year":"1999","unstructured":"Svensson EC, Tufts RL, Polk CE, Leiden JM (1999) Molecular cloning of FOG-2: a modulator of transcription factor GATA-4 in cardiomyocytes. Proc Natl Acad Sci U S A 96(3):956\u2013961","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2499_CR47","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/appi.ajp.163.8.1438","volume":"163","author":"DE Tenback","year":"2006","unstructured":"Tenback DE, van Harten PN, Slooff CJ, van Os J (2006) Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 163(8):1438\u20131440","journal-title":"Am J Psychiatry"},{"issue":"19","key":"2499_CR48","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1242\/dev.129.19.4627","volume":"129","author":"SG Tevosian","year":"2002","unstructured":"Tevosian SG, Albrecht KH, Crispino JD, Fujiwara Y, Eicher EM, Orkin SH (2002) Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2. Development 129(19):4627\u20134634","journal-title":"Development"},{"issue":"13","key":"2499_CR49","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/mds.22098","volume":"23","author":"M Tinazzi","year":"2008","unstructured":"Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, Pilleri M, Moretto G, Fiaschi A, Smania N, Giorgetti P, Antonini A (2008) [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 23(13):1825\u20131829","journal-title":"Mov Disord"},{"issue":"6","key":"2499_CR50","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00415-009-5039-0","volume":"256","author":"M Tinazzi","year":"2009","unstructured":"Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, Fiaschi A, Ottaviani S (2009) Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 256(6):910\u2013915","journal-title":"J Neurol"},{"issue":"9","key":"2499_CR51","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/archpsyc.65.9.1062","volume":"65","author":"EJ Oord van den","year":"2008","unstructured":"van den Oord EJ, Kuo PH, Hartmann AM, Webb BT, M\u00f6ller HJ, Hettema JM, Giegling I, Buksz\u00e1r J, Rujescu D (2008) Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry 65(9):1062\u20131071","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"2499_CR52","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.109.065656","volume":"51","author":"A Varrone","year":"2010","unstructured":"Varrone A, Halldin C (2010) Molecular imaging of the dopamine transporter. J Nucl Med 51(9):1331\u20131334","journal-title":"J Nucl Med"},{"issue":"3","key":"2499_CR53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/jnnp.74.3.294","volume":"74","author":"A Winogrodzka","year":"2003","unstructured":"Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC (2003) [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 74(3):294\u2013298","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-011-2499-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2499-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T21:13:30Z","timestamp":1741727610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-011-2499-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,24]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1007\/s00213-011-2499-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,24]]}}}